 AIM ImmunoTech Inc NYSE:AIM announced that its Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer LAPC has commenced after its trial protocol received approval from an Institutional Review Board IRB. The companys Phase 2 study Investigational New Drug IND application for Ampligen was previously cleared by the US Food and Drug Administration FDA. 